Non-Invasive Monitoring Systems Announces Successful Experimental Study of Cardiopulmonary Resuscitation Using Its Patented Motion Platform.

Business Editors/Health & Medical Writers

MIAMI BEACH, Fla.--(BUSINESS WIRE)--Nov. 13, 2001

Non-Invasive Monitoring Systems, Inc. (OTCBB:NIMU) announced the publication of a paper on cardiopulmonary resuscitation in the October 2001 issue of Resuscitation by Dr. Jose Adams and his group at the Mount Sinai Medical Center in Miami Beach, Fla. This experimental study in animals involved stopping the heart for 18 minutes while treating solely with Non-Invasive Monitoring System's motion platform. The device moved the body headward to footward and vice-versa while lying flat 120 times a minute to non-invasively provide overall blood flow comparable to open chest heart massage, the optimal means for supporting circulation during cardiac arrest. The motion platform also solely provided for breathing without the requirement of a mechanical ventilator. All animals in this study survived. The motion platform preserved brain and cardiac blood flow during the period of cardiac arrest. The forces associated with the motion platform treatment fell within the range that a mother imparts to her baby while pushing a carriage back and forth as reported in a preliminary study at the European Respiratory Society in Berlin in September 2001.

Dr. Marvin Sackner, Chairman of the Board of Directors on Non-Invasive Monitoring Systems, commented as follows. "Dr. Adams' paper on CPR is the fourth in a series of peer reviewed, scientific papers on the applications of the motion platform since December 2000. He and his associates have demonstrated that this technology can serve as a sole non-invasive substitute for mechanical ventilator support of paralyzed animals with normal as well as diseased lungs. The addition of pulses to the circulation, brought about by the platform movement of periodic acceleration, also causes release of beneficial mediator substances from the lining of blood vessels. Such mediators are also released during aerobic exercise except that the heart rate does not change during motion platform treatment. Dr. Adams found that these mediators lowered blood pressure to normal within the lungs when it was experimentally elevated. Further, the motion platform through release of beneficial mediators from blood vessel linings, principally nitric oxide, substantially increased blood flow to the heart and brain as well as other organs. The current study indicated that the motion platform appeared to an efficient means for cardiopulmonary resuscitation. Taking into account the varied applications of the motion platform technology, this body of work may herald a new non-invasive, treatment discipline of medicine, Acceleration Therapeutics." Dr. Sackner added that Non-Invasive Monitoring Systems has fabricated several prototype, adult, motion platforms and in preliminary investigations found that nitric oxide appears to be released in normal subjects during well-tolerated usage of this technology. Plans are underway to submit the motion platform to FDA for approval to conduct rigorous clinical trials in order to gain approval to market this technology.

Non-Invasive Monitoring Systems, Inc. (the "Company" or "Nims") is engaged in research, development and marketing of computer assisted, non-invasive monitoring devices and related software designed to detect abnormal respiratory, cardiac, and other medical conditions from sensors placed externally on the body's surface. These devices provide diagnostic information regarding cardio-respiratory and sleep disorders in infants, children and adults; in addition, alarms are sounded for adverse cardiac and respiratory events in critically ill patients. The Company also has developed a non-invasive, periodic acceleration, motion platform that it intends to commercialize for treatment of cardiovascular disease.

Except for historical information, this press release contains, forward-looking statements regarding the Company's operations, performance, financial condition, business strategies, margins and sales information and are made pursuant to the "safe harbor" provisions of the private securities litigation reform act of 1995. For this purpose, any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. These statements by their nature involve substantial risks and uncertainties, certain of which are beyond the Company's control, and actual results could differ materially depending on a variety of important factors, including those described in this press release and the Company's filings with the Securities and Exchange Commission. The Company undertakes no obligations to revise or update any forward-looking statements in order to reflect events or circumstances that may arise after the date of this release.